Filing Flows › Health Care › Neuronetics (STIM)
Neuronetics (STIM) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Neuronetics (STIM) Q3 2026 earnings results →
Q3 2026 Revenue up 12% year over year to $42.0M · 4¢ of every $1 of revenue lost · operating margin 1.3%
Neuronetics made $42.0M in Q3 2026 (+12% Y/Y): Service $26.2M, NeuroStar $15.8M. Operating margin 1.3%, net loss $1.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $42.0M in Q3 2026, up 13% year over year and up 1% from the previous quarter. Service was the largest line at 62% of revenue. Service added $4.4M year over year (up 20%), 94% of the total change.
Gross margin was 52.2%, up 6.3 points from Q3 2025. Operating profit was $541K, a 1.3% margin (up 20.9 points year over year). Operating expenses fell 13% while revenue rose 13%. The quarter ended with a net loss of $1.6M, narrower than the previous quarter's $3.5M loss. Net interest and other expense of $2.1M was the main reason.
Operating cash flow was $1.2M. Non-cash charges added back $742K of depreciation and amortization and $178K of share-based compensation. Working capital and other items added $1.9M. Capital expenditures of $470K left free cash flow of $768K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $42.0M | +12% | 1.3% | −$1.6M | $1.2M |
| Q2 2026 | 10-Q | Aug 11, 2026 | $41.6M | +9% | -3.6% | −$3.5M | −$1.0M |
| Q1 2026 | 10-Q | May 5, 2026 | $34.5M | +8% | -26.1% | −$10.8M | −$9.4M |
| Q4 2025 | 10-K | Mar 17, 2026 | $41.8M | +140% | -12.1% | −$7.2M | $882K |
| Q3 2025 | 10-Q | Nov 4, 2025 | $37.3M | +101% | -19.6% | −$9.4M | −$785K |
| Q2 2025 | 10-Q | Aug 5, 2025 | $38.1M | +132% | -21.1% | −$9.8M | −$3.5M |
| Q1 2025 | 10-Q | May 6, 2025 | $32.0M | +84% | -34.4% | −$12.7M | −$17.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Neuronetics
Neuronetics, Inc. (the “Company” or “Neuronetics” or the “Registrant”) believes that mental health is as important as physical health. As a global leader in neuroscience, the Company is delivering more treatment options to patients and healthcare providers by offering exceptional in-office treatments that produce extraordinary results. The Company’s first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (“TMS”), to create a pulsed, magnetic resonance imaging (“MRI”)-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
In its own words, from its 10-K, filed Mar 17, 2026.
Neuronetics against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +12% against the peers' median +5%. Operating margin: 1.3% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| STIM Neuronetics | Q3 2026 | $42.0M | +12% | 1.3% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Neuronetics 10-Q on SEC EDGAR · CIK 1227636 · Surgical & Medical Instruments & Apparatus
Guidance and outlook
13F: who owns STIM and who is buying
More on STIM
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results